StockData
Pluri Inc. logo

Pluri Inc. (PLUR) stock analysis

PLURNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30
Financials through Q1 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/30
$1.05−0.04 (-3.67%)

Close on Nov 13, 2026Market cap $12.96MP/E –Yield –

StockData Score

Prices as of Nov 13, 2026How the score works

Value0Growth3Performance1Health0Dividend0

Weak4 of 30 checks passed

Pluri passes 4 of the 30 checks behind our score; 20 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
0/6
Growth
3/6
Past performance
1/6
Financial health
0/6
Dividend
0/6

What stands out

  • Revenue growing 10%+ a year

    Revenue grew 52.4% a year over the last three fiscal years.

  • Growing faster than the industry

    Revenue grew 10.0% over the last twelve months; the Drugs median is 7.7%.

  • Gross margin improving

    Gross margin was 52.0% over the last twelve months, against 42.9% a year earlier.

  • Net margin above its 5-year average

    Net margin was -1944% over the last twelve months, against a 5-year average of -7587%.

What to watch

  • Interest not well covered

    Operating income covers interest expense -36.8 times; we look for at least 5.

  • Elevated bankruptcy risk

    The Altman Z-score is -32.23; above 3 is the safe zone and below 1.8 the distress zone.

  • P/S above the industry

    Pluri's price-to-sales of 8.88 is above the Drugs median of 4.73 (book value is negative, so we use sales).

  • Net margin below the industry

    Pluri's net margin of -1944% is below the Drugs median of -53.5%.

Valuation0/6

  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E against the industry

    Needs positive earnings and enough profitable companies in the industry.

  • EV/EBITDA against its history

    Needs positive EBITDA and price history.

  • P/S above the industry

    Pluri's price-to-sales of 8.88 is above the Drugs median of 4.73 (book value is negative, so we use sales).

  • Price against fair value

    We could not estimate a fair value: it needs at least two valuation methods with positive inputs.

  • Margin of safety

    Depends on the fair value estimate.

Growth3/6

  • Revenue growing 10%+ a year

    Revenue grew 52.4% a year over the last three fiscal years.

  • EPS growth over 3 years

    Needs positive EPS three years ago and today.

  • Earnings acceleration

    Needs positive net income now, a year ago and five years ago.

  • Growing faster than the industry

    Revenue grew 10.0% over the last twelve months; the Drugs median is 7.7%.

  • Company guidance

    No outlook found in earnings releases from the last twelve months.

  • Gross margin improving

    Gross margin was 52.0% over the last twelve months, against 42.9% a year earlier.

Past performance1/6

  • Return on equity

    Needs positive equity and five years of results.

  • Return on invested capital

    Needs operating income and invested capital.

  • Return on equity against the industry

    Needs positive equity.

  • Earnings over 5 years

    Needs positive net income five years ago and in the latest year.

  • Net margin above its 5-year average

    Net margin was -1944% over the last twelve months, against a 5-year average of -7587%.

  • Net margin below the industry

    Pluri's net margin of -1944% is below the Drugs median of -53.5%.

Financial health0/6

  • Debt level

    Needs debt and equity figures.

  • Debt trend

    Needs a balance sheet from five years ago with positive equity.

  • Debt coverage

    Needs operating cash flow.

  • Interest not well covered

    Operating income covers interest expense -36.8 times; we look for at least 5.

  • Short-term assets don't cover short-term debts

    Current assets are 0.27 times current liabilities.

  • Elevated bankruptcy risk

    The Altman Z-score is -32.23; above 3 is the safe zone and below 1.8 the distress zone.

Dividend0/6

  • No dividend

    Pluri has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Fair value

How we estimate it

We don't publish a fair value for Pluri. It needs a US-dollar share price, at least two valuation methods with positive inputs (earnings, EBITDA, book value or sales) and, for companies with several share classes, classes that trade at the same price.

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • P/B at month end
  • Own 5-year median 1.6
  • Drugs median 2.1

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

High risk

Average value traded per day
$57.41K
Value traded per 1% price move
$3.31K

Downside

High risk

Typical loss in a bad month
35.8%
Volatility (annualized)
73%
Sharpe ratio, 1 year
-1.11
Beta to the S&P 500 (5Y)
0.95

Typical bad-month loss, week by week

25%: high

Margins

Share of revenue, fiscal years 2012 to 2026

Gross margin

44.6%

Operating margin

-2454.5%

Net margin

-2344.6%

See a number that looks wrong?